88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
28 citations
,
February 2020 in “Clinical Ophthalmology” Certain medications and patient factors increase the risk of Intraoperative Floppy Iris Syndrome during cataract surgery, but with careful planning and technique adjustments, complications can be minimized.
1 citations
,
February 2025 in “Notulae Scientia Biologicae” Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
19 citations
,
September 2009 in “Journal of Chemical & Engineering Data” Flutamide, dutasteride, and finasteride dissolve differently in supercritical carbon dioxide, with dutasteride dissolving the least.
July 2024 in “Reactions Weekly”
June 2019 in “Reactions Weekly” 1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
December 2025 in “PubMed” The minoxidil and finasteride foam remains stable and effective for 180 days at room temperature.
13 citations
,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
13 citations
,
January 2018 in “International Journal of Dermatology” The study found that treatment improved hair condition in patients with Fibrosing Alopecia in a Pattern Distribution in Chile.
102 citations
,
April 2014 in “International Journal of Dermatology” The treatment helped reduce symptoms and stabilize the hairline in most patients with Frontal Fibrosing Alopecia, but hair regrowth was limited.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
April 2012 in “Informa Healthcare eBooks” Fibrosing alopecia in a pattern distribution is a unique hair loss condition with inflammation and scarring, resembling but distinct from common balding.
8 citations
,
December 2008 in “Journal of The American Academy of Dermatology” Finasteride can cause a unique skin reaction on the penile shaft.
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
5 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” MorrF improves hair growth better than minoxidil alone.
These medications for BPH have known risks and may have new side effects.
7 citations
,
October 2015 in “Actas Dermo-Sifiliográficas” New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.
17 citations
,
June 2016 in “Australasian Journal of Dermatology” Treatment with dutasteride, minoxidil, and artificial hair transplantation improved appearance but caused folliculitis.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
P-3074 effectively blocks scalp DHT better than oral finasteride.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
May 2022 in “International Journal of Trichology”
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Farudodstat may effectively treat alopecia areata without harmful side effects.
May 2025 in “Skin Appendage Disorders” Frontal fibrosing alopecia can be diagnosed by examining facial areas and treated with specific medications to stop its progression.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
June 2026 in “International Journal of Pharmaceutics”